To clarify the role of endogenous GPR39 and identify the potential for pharmacological modification of GPR39 activity to modify glucose-stimulated insulin secretion and be a potential treatment for T2D, we have identified potent and selective GPR39 agonists and tested their acute insulinotropic effects in normal mice and in rodent models of T2D. Here, INS is linked to type 2 diabetes mellitus.